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Abstract
The live oral poliovirus vaccine (OPV) strains are genetically unstable, causing, in rare cases, vaccine-associated paralytic poliomyelitis.
Reversions of the known attenuating mutations in OPV strains and intertypic recombination have been identiﬁed as the underlying
causes of the increased neurovirulence of poliovirus isolates. In this study, three OPV isolates (one non-recombinant and two recombi-
nants) were tested in order to correlate phenotypic traits such as temperature sensitivity (Rct test) and growth kinetics (one-step
growth curve test) with mutations and recombination events of the viral genome. Moreover, the immunity level of the western Greek
population aged 1–40 years was evaluated against OPV isolates and Sabin vaccine strains, with a microneutralization assay. Members of
the 1–40-year age group (both pooled and individual sera) showed no signiﬁcant differences in neutralization test (NT) titres against
OPV isolates in comparison with the Sabin vaccine strains. However, all three OPV isolates showed reverted phenotypic traits in Rct
or one-step growth curve assays. The results of our study revealed a signiﬁcant decrease in immunity level from the 1–10-year age
group to the 21–30-year age group (pooled sera) for both poliovirus types 1 and 3. For both poliovirus types, the highest NT titres
were observed in the 1–10-year age group, and the lowest NT titre was observed in the 21–30-year age group, towards poliovirus
type 3. Our study underlines the need for immunological studies in all age groups, in order to allow reconsideration of the current
vaccination policies and to avoid epidemics caused by the circulation of highly evolved OPV derivatives.
Keywords: Greece, immunity, mutations, neurovirulence, oral poliovirus vaccine isolates, polioviruses, recombination
Original Submission: 15 September 2010; Accepted: 10 January 2011
Editor: T. A. Zupanc
Article published online: 24 January 2011
Clin Microbiol Infect 2011; 17: 1554–1562
10.1111/j.1469-0691.2011.03470.x
Corresponding author: P. Markoulatos, Department of
Biochemistry & Biotechnology, School of Health Sciences, University
of Thessaly, Ploutonos 26 & Aiolou, 41221 Larissa, Greece
E-mail: markoulatos@bio.uth.gr
Introduction
Polioviruses are the aetiological agents of acute paralytic
poliomyelitis, belong to the genus Enterovirus of the family
Picornaviridae, and exist as three immunologically deﬁned
serotypes (P1, P2 and P3). The genome of polioviruses is a
7.5-kb positive-sense single-stranded polyadenylated RNA.
The viral RNA contains a long open reading frame ﬂanked by
a 5¢-noncoding region (5¢-NCR) and a 3¢-noncoding region,
which are involved in viral replication and translation. The
structural (VP4, VP2, VP3 and VP1) and non-structural (2A,
2B, 2C, 3A, 3B, 3C and 3D) viral proteins are produced by
translation of the coding region and proteolytic cleavage of
the polyprotein [1]. The poliovirus capsid consists of 60
copies of each of the four structural virion proteins. Surface-
exposed loops of structural proteins VP1, VP2 and VP3
contain the four antigenic sites designated AgS1–AgS4 [2].
Since 1960, poliomyelitis has been effectively controlled by
the use of inactivated poliovirus vaccine (IPV) or live oral
poliovirus vaccine (OPV). OPV consists of attenuated and
thermosensitive strains of each of the three serotypes
(Sabin 1, 2 and 3). The molecular determinants of attenua-
tion and temperature sensitivity have been intensively stud-
ied, to elucidate the mechanisms involved and to improve
the safety of Sabin vaccine strains [3–5].
OPV was the vaccine adopted throughout most of the
world by 1964, because it multiplies actively in the gut of
vaccinees, eliciting a strong, long-lasting immune response,
and local immunity induced by OPV prevents or limits
re-infection of humans. However, the selection of variants
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with increased neurovirulence, caused by genetic instability,
constituted a real problem with respect to OPV safety [6–8].
In rare cases (one case per 750 000 primary vaccinees), OPV
strains have been implicated in vaccine-associated paralytic
poliomyelitis (VAPP). Genetic recombination and mutations
at attenuating sites of the genome have been associated with
the emergence of VAPP cases [9,10]. Moreover, changes are
frequently observed in the antigenic properties of OPV
strains, representing a selection of viral variants that are less
prone to be neutralized by human antibodies [11].
OPV was introduced into Greece in 1964, and was admin-
istrated to 2 million persons aged <18 years. A standard vac-
cination schedule of four doses at the ages of 2, 4, 6 and
18 months, with a booster dose at 4–6 years, led to the elimi-
nation of indigenous cases of poliomyelitis after 1982 [12].
However, Greece has switched to the exclusive use of IPV
since 2005, as is also the case in most polio-free countries.
In this study, three OPV isolates (one non-recombinant
and two recombinants) were tested in order to correlate
the reverted phenotypic traits, such as temperature sensitiv-
ity and growth kinetics, with mutations and recombination
events in the viral genome. Moreover, the immunity level of
the western Greek population aged 1–40 years was evalu-
ated against OPV isolates and Sabin vaccine strains.
Materials and Methods
Virus isolation
Two viral strains were isolated from faecal samples of a
VAPP patient or a healthy vaccinee and one from the envi-
ronment during the time period 1978–1985. They were
recultured for the purpose of the present study in Hep-2
cells (Table 1), as previously described [13]. The vaccine
strains (Sabin 1, 2 and 3) that were used in this study were
provided by the WHO.
Genotyping and identiﬁcation of recombinant OPV isolates
Primer pair UG52/UC53 was used for identiﬁcation of vac-
cine origin and for genotyping of the isolates in the 5¢-NCR
[14]. Also, the genotype of isolates according to VP1 capsid
protein was determined by sequencing. The primer pairs
used for complete VP1 gene sequencing were UG1/222
[15,16] for the ﬁrst half of the VP1 gene and serotype-spe-
ciﬁc primer pairs S137/S1688 and S326/S3651 for Sabin 1
and Sabin 3 isolates, respectively, for the second half of the
VP1 gene [17].
Identiﬁcation of recombination sites of OPV isolates was
initially performed by restriction fragment length polymor-
phism screening analysis followed by sequencing, as previ-
ously described [18,19].
Extraction of viral RNA
Two hundred microlitres of frozen and thawed viral stocks
were subjected to viral RNA extraction as previously
described [20].
Sequencing of OPV isolates
Reverse transcription and PCR reactions for OPV isolates
were performed with an MJ Research Minicycler, as previ-
ously described [19].
Complete genomic sequencing of isolate MB1 and
sequencing of VP1–VP4 capsid genes of isolates 522 and 742
were performed. Also, the partial 5¢-NCR sequences of iso-
lates 522 and 742 were determined with primer pair UG52/
UC53. The primer pairs used in this study are shown in
Table 2. For all primer pairs, PCR conditions were as
described in the original publications (Table 2). Analysis of
PCR products was performed by agarose gel electrophoresis
(2% agarose; 1 mg/L ethidium bromide in Tris–boric acid–
EDTA buffer), with the 100-bp DNA ladder as molecular
mass marker (Invitrogen Life Technologies, Paisley, UK).
PCR products were cleaned up with a PCR gel extraction kit
(Qiagen, Hilden, Germany). All PCR products were
sequenced at Macrogen Inc.
Computational analysis/computer graphics
ClustalW was used for alignment of nucleotide and amino
acid sequences of OPV isolates with those of the reference
strains cited in GenBank (Sabin 1, AY184219; Sabin 2,
TABLE 1. Available data for oral
poliovirus vaccine isolates
Isolate
5¢-NCR
and VP1
genotype Source
Recombination
site/type/junction
Accession numbersa
5¢-NCR/Capsid/2A–3D Reference
522 S1 Healthy vaccinee Non-recombinant FJ609754/HM537000/– [21]
742 S1 Environment 2A S1/S3 3461–3465
2C S3/S2 4511–4527
EU598472/HM537002/EU598488 [19]
MB1 S3 VAPP 2C S3/S1 4880–4887 GU180608 This study
5¢-NCR, 5¢-noncoding region.
aThe accession number of isolate MB1 refers to the complete genome. The 2A–3D genomic region of isolate 522
was not sequenced.
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AY184220; and Sabin 3, AY184221). Amino acid sequences
of OPV isolates were obtained with Gene-Runner V. 3.05.
Rasmol V. 2.7.1.1 (http://www.umass.edu/microbio/rasmol)
was used for depiction of the amino acid substitutions, which
were identiﬁed in the capsid proteins of OPV isolates. For
visualization of the observed amino acid substitutions, the
capsid protomer structure of the poliovirus type 1 Mahoney
strain (1ASJ.pdb) was used for Sabin 1 isolates, and the
structure of the poliovirus type 3 Sabin strain (1VBE.pdb)
was used for Sabin 3 isolates.
Rct marker test
Reproductive capacities at different temperatures (Rct mar-
ker) were evaluated with the Rct test. The Rct value is
deﬁned as the difference between the log10 virus titre of a
viral stock measured at the optimal temperature (37C) and
that measured at the supraoptimal temperature (40C). Rct
values of OPV isolates and Sabin vaccine strains were deter-
mined as previously described [13]. Viruses were considered
to be thermosensitive if the Rct value (between 37 and
40C) was greater or equal to 2.00, and thermoresistant if
the Rct value was lower than 2.00.
One-step growth curve experiment
One-step growth curve experiments were performed in
Hep-2 cells at 37C and 40C for 0–16 h, with a multiplicity
of infection of 10 (determined by titration of virus stocks on
Hep-2 cells), as previously described [13].
Neutralization assay with human sera
The level of immunity of the human population against polio-
virus was determined with a microneutralization assay, as
previously described [21]. Pooled sera (ten mixed serum
samples) were used from each age group (1–10, 11–20,
TABLE 2. Primer pairs used for
ampliﬁcation of the complete gen-
ome of isolate MB1 and of the par-
tial 5¢-noncoding region (5¢-NCR)
and capsid region of isolates 522
and 742
Primera Polarity Sequence (5¢ ﬁ 3¢)b Reference
72437 Sense 001-TTAAAACAGCTCTGGGGTTG-020 [31]
216616 Antisense 545-GGAACACGGACACCCAAAGTA-565 [32]
UG52* Sense 162-CAAGCACTTCTGTTTCCCCGG-182 [14]
UC53* Antisense 577-ACCGACCAATACCACTGTT-595 [14]
S3309 Sense 309-GTAGCTTGGGCCGATGAGT-327 [33]
S3044 Antisense 1025-ACTGAATTTGCTGCCTCCTG-1044 [33]
S3936 Sense 936-CTCCAGCACTCAATTCACCA-955 [33]
S3510 Antisense 1491-TCCCAGTAACACCCCACATC-1510 [33]
S378 Sense 1378-TTATGCAAATGCGAATCCAG-1397 [33]
S3864 Antisense 1844-AATAGGCGGAGTGACATCAAA-1864 [33]
S3709 Sense 1709-CCCAATGTGTAGCGAGTTCA-1728 [33]
S3218 Antisense 2200-GTGCCCAACATAGCCTCCT-2218 [33]
S340 Sense 2140-TACGGGGAAAATCCTAGTGG-2159 [33]
S3659 Antisense 2640-CGTTTGAACTGTGTCGGATG-2659 [33]
UG1 Sense 2402-TTTGTGTCAGCGTGTTAATG-2421 [15]
222 Antisense 2982-CICCIGGIGGIAYRWACA-2999 [16]
S326 Sense 2826-GCCGTAAGTTGGAGTTTTTCAC-2847 [17]
S3651 Antisense 3451-CTCCTTAGTGGCGAGATGGTAG-3430 [17]
S123* Sense 323-GAGTCTGGACATCCCTCACC-342 [34]
S1976* Antisense 957-TACCCGCAAGCCTCTATGTT-976 [34]
S182* Sense 882-CTCAAGACCCTTCCAAGTTCA-902 [34]
S1542* Antisense 1523-ATTATCTGGTGCGGGAACAC-1542 [34]
S1350* Sense 1350-GGGATAGCAACACCACTACCA-1370 [34]
S1693* Antisense 1675-TGGAATCTCTGGGGAGGAC-1693 [34]
S1476* Sense 1476-CGGTGGATTACCTCTTTGGA-1495 [34]
S1154* Antisense 2136-AGTTTGCCAGTTGCCATCA-2154 [34]
S1013* Sense 2013-TCTGCCTGTCACTCTCTCCA-2032 [34]
S1669* Antisense 2648-TGGTTTGCACTGTATCAGAAGG-2669 [34]
S137* Sense 2837-AGGAAATTGGAGTTCTTCACC-2857 [17]
S1688* Antisense 3488-ACATGACGTTCACTGCGTTTT -3468 [17]
71935 Sense 3206-GTCAATGATCACAACCC-3222 [35]
EUC2 Antisense 4454-TTTGCACTTGAACTGTATGTA-4474 [36]
UG23 Sense 4169-AAGGGATTGGAGTGGGTGTC-4188 [37]
UC15 Antisense 4948-CATCTCTTGAAGTTTGCT-4965 [37]
S3141 Sense 4741-AGGCATTCTGTTCACATCCAAC-4763 [18]
S3368 Antisense 5239-ATGTTGACGATCCATCCTTTCT-5217 [18]
S248 Sense 4968-TCCTTTAGTGTGTGGCAAGG-4988 [18]
S2911 Antisense 5812-GTTTGTCGTCCACCGAGATT-5832 [18]
UG16 Sense 5921-GTTGGTGGGAACGGTTCACA-5940 [37]
UC12 Antisense 6516-TCAATTAGTCTGGATTTTCCCTG-6494 [37]
S170 Sense 5769-TATGTATGTTCCTGTCGGTGCT-5791 [18]
S1450 Antisense 6851-ATTGAAGTGCCTGAGCAACC-6871 [18]
S1198 Sense 6728-GCACTAAAGATGGTGCTTGAGAAA-6752 [18]
S1885 Antisense 7415-CTACAACAGTATGACCCAATCCAA-7391 [18]
S2107 Sense 6647-TCCCAGTGCTAATGGAAGAGA-6668 [18]
S2872 Antisense 7393-ACAACAGCATGACCCAATCC-7413 [18]
aPrimer pairs marked with an asterisk were used for ampliﬁcation of the partial 5¢-NCR and capsid region of iso-
lates 522 and 742. Primer pair UG1/222 was used for ampliﬁcation of all three isolates.
bPositions refer to Sabin types according to primer notiﬁcation (accession numbers: S1, Sabin 1 strain, AY184219; S2,
Sabin 2 strain, AY184220; S3, Sabin 3 strain, AY184221). For all other primers, positions refer to Sabin 1 strain.
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21–30 and 31–40 years) for the neutralization test (NT). The
serum samples were provided by volunteers from regions of
western Greece during the time period 2009–2010.
Moreover, the immunity level against poliovirus of two
individuals randomly selected from each age group (1–10,
11–20, 21–30 and 31–40 years) was determined with the
same microneutralization assay.
Statistical analysis
Student’s t-test (paired samples test) was used to compare
the mean values of log10 reciprocal NT titres of four age
groups (1–10, 11–20, 21–30 and 31–40 years; pooled sera of
ten individuals for each) against each Sabin vaccine strain
(Sabin 1 or Sabin 3) with those against each OPV isolate of
the same serotype. It was also used to compare the mean
values of log10 reciprocal NT titres of four age groups (1–10,
11–20, 21–30 and 31–40 years; two individual sera for each)
against each Sabin vaccine strain (Sabin 1 or Sabin 3) with
those against each OPV isolate of the same serotype.
A one-way ANOVA (Duncan’s multiple range test) was
used to compare the mean values of log10 reciprocal NT ti-
tres against all polioviruses of the same serotype between
the 1–10-year, 11–20-year, 21–30-year and 31–40-year age
groups (pooled sera of ten individuals each). It was also used
to compare the mean values of log10 reciprocal NT titres
against all polioviruses of the same serotype between the 1–
10-year, 11–20-year, 21–30-year and 31–40-year age groups
(sera of two individuals for each).
Student’s t-test was used to compare the mean values of
log10 reciprocal NT titres of four age groups (1–10, 11–20,
21–30 and 31–40 years) against each poliovirus strain shown
in the neutralization assay of pooled sera with those of indi-
vidual sera.
Results
Genotypes and recombination types of OPV isolates
The 5¢-NCR and VP1 genotypes of isolates were identiﬁed.
Two strains were genotyped as Sabin 1 and one strain as
Sabin 3 (Table 1). Among the three isolates, one (522) was
identiﬁed as non-recombinant, and two, MB1 and 742, as
recombinant in one or two sites, respectively. The recombi-
nation type was S3/S1 for isolate MB1, and the recombina-
tion site was located in the 2C genomic region, from
nucleotides 4880 to 4887. Isolate 742 was identiﬁed previ-
ously as S1/S3/S2 recombinant, with the ﬁrst recombination
site located in the 2A region from nucleotides 3461 to 3465
and the second in the 2C region from nucleotides 4511 to
4527 (Table 1).
Temperature sensitivity of OPV isolates
The non-recombinant Sabin 1 isolate 522 and the recombi-
nant Sabin 3 isolate MB1 showed a thermosensitive pheno-
type, with Rct values of 3.5 and 4.5 units, respectively. The
bi-recombinant Sabin 1 isolate 742 showed partial reversion
to a thermoresistant phenotype, with an Rct value of
2.00 units. The Sabin vaccine strains (Sabin 1 and Sabin 3)
exhibited, as expected, Rct values greater than 2.00 units
(Table 3).
One-step growth curve experiment
The growth rates and virus yields of each isolate were com-
pared with those of the corresponding genotype of the Sabin
vaccine strain (Sabin 1 or Sabin 3) in one-step growth exper-
iments in Hep-2 cells at 37C and 40C.
The non-recombinant Sabin 1 isolate 522 showed different
growth kinetics from that of its progenitor Sabin 1 vaccine
strain (Fig. 1). More speciﬁcally, isolate 522 showed 1.5–
2.5 log10 units higher viral yield than the Sabin 1 vaccine
strain at both 37C and 40C during the infectious life cycle.
TABLE 3. Location of mutations in the 5¢-noncoding region
and capsid region sequences of oral poliovirus vaccine
(OPV) isolates, and comparison with the corresponding
nucleotide and amino acid positions in Sabin vaccine strains
Origin Region Isolate Mutationsa D log Rct-40
S1 5¢-NCR 522 U344C
G480A
C583G
3.5
S1 5¢-NCR 742 G480A
C583G
2.0
S3 5¢-NCR MB1 U472C 4.5
S1 VP2 522 C1119A, Asp56 ﬁ Glu
G1207A
G1479A
C1695U
S1 VP2 742 C1441U
S3 VP2 MB1 –
S1 VP3 522 G1775U, Val4 ﬁ Ile
C1941A, Ala59 ﬁ Glu
G2003A, Asp80 ﬁ Asn
S1 VP3 742 –
S3 VP3 MB1 A2207U
U2208G, Met149 ﬁ Trp
S1 VP1 522 A2623G
A2749G, Ile90 ﬁ Met
A3248G, Ile257 ﬁ Val
S1 VP1 742 G2502A, Ser8 ﬁ Asn
G2776U, Lys99 ﬁ Asn
A2833G
U2904G, Phe142 ﬁ Cys
S3 VP1 MB1 C2493U, Thr6 ﬁ Ile
C2855A
U2857A
C2863A, Asp129 ﬁ Glu
U2865G, Met130 ﬁ Arg
G2882U, Val136 ﬁ Leu
A3248G, Ile258 ﬁ Val
Numbering according to vaccine strains Sabin 1 (AY184219) and Sabin 3
(AY184221). Reproductive capacity values of OPV isolates and Sabin vaccine
strains at different temperatures (Rct marker) are also indicated.
aThe ﬁrst nucleotide or amino acid refers to the Sabin vaccine strain. Amino
acid substitutions situated near or in antigenic sites are underlined. No muta-
tions were identiﬁed in VP4 capsid protein of all three isolates.
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However, the growth of isolate 522 showed a ﬂat curve at
40C, like that of the Sabin 1 vaccine strain. The bi-recombi-
nant Sabin 1 isolate 742 replicated with kinetics similar to
those of its progenitor Sabin 1 vaccine strain, showing that
the virus yield rose 2 h post-infection at 37C (Fig. 1),
whereas at 40C its growth was blocked, as it was also for
the Sabin 1 vaccine strain.
The recombinant Sabin 3 isolate MB1 showed different
growth kinetics from that of its progenitor Sabin 3 vaccine
strain (Fig. 1). More speciﬁcally, the viral yield of isolate MB1
rose 2 h post-infection at 37C, whereas that of the Sabin 3
vaccine strain rose 4 h post-infection. This initial difference
resulted in a 1.5 log10 units higher viral yield of isolate MB1
than of the Sabin 3 vaccine strain 4 h post-infection. However,
isolate MB1 showed a similar viral yield to that of the Sabin 3
vaccine strain at the ﬁnal stages of the infectious life cycle (8
and 16 h post-infection). At 40C, the growth of isolate MB1
was blocked, as was that of the Sabin 3 vaccine strain.
Nucleotide and amino acid sequence analysis
Table 3 shows the 5¢-NCR and capsid sequence differences of
OPV isolates with respect to Sabin vaccine strains. Both
Sabin 1 isolates (522 and 742) displayed the mutation G480A
in the 5¢-NCR, which has been correlated with reversion to
neurovirulence and thermoresistance [7]. They also displayed
the mutation C583G, which has been observed in isolates of
previous studies [13,22], and may confer a selective advantage.
In VP1 of isolate 522, the amino acid substitution Ile90 ﬁ Met
is situated in the exterior of the capsid, near AgS1 [2]. The
amino acid substitution Ile257 ﬁ Val is partially exposed at
the outer surface of the virion, situated on the last strand of
VP1, which is located next to strand B, where residue 90 is
located (data not shown). The amino acid substitution
Lys99 ﬁ Asn in VP1 of isolate 742, which is highly exposed in
the exterior of the capsid, is located in AgS1 as well as in the
VP1 BC loop, which participates in the formation of the north
rim of the canyon and is involved in the binding of receptor
CD155 to the virus [2,23]. The amino acid substitution
Phe142 ﬁ Cys is exposed on the external surface of the vir-
ion in the DE loop (data not shown), and may contribute to
restoring neurovirulence, like residue 143, a well-known
determinant of neurovirulence in Sabin 2 isolates [6]. The
amino acid substitutions Ala59 ﬁ Glu and Asp80 ﬁ Asn in
VP3 of isolate 522 are located in AgS3 and near AgS4, respec-
tively [2]. The amino acid substitutions Asp56 ﬁ Glu in VP2
and Val4 ﬁ Ile in VP3 of isolate 522, as well as Ser8 ﬁ Asn
in VP1 of isolate 742, are situated in the N-terminus of capsid
proteins, which participates in hydrophobic interactions con-
tributing to the stability of the virion [24].
The Sabin 3 isolate MB1 displayed the mutation U472C in
the 5¢-NCR, which has been correlated with reversion to
neurovirulence and thermoresistance [8,10]. In the VP1 cod-
ing region, it displayed the reversion at nucleotide 2493
(C ﬁ U (Thr6 ﬁ Ile)), which is a determinant of attenuation
[25]. The amino acid substitutions Asp129 ﬁ Glu and
Met130 ﬁ Arg are situated in the bottom of the canyon
(data not shown), and may be involved in the interaction of
receptor CD155 with the virus. The amino acid substitutions
Val136 ﬁ Leu and Ile258 ﬁ Val are partially exposed at the
outer surface of the virion, and are situated in the hydrocar-
bon-binding pocket of VP1, interacting with a sphingosine
molecule (data not shown). The amino acid substitution
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FIG. 1.One-step growth curve analysis of oral poliovirus vaccine
isolates 522, 742 and MB1 in comparison with Sabin vaccine strains
in Hep2 cells. Cells were infected at a multiplicity of infection of 10,
and incubated at 37C or 40C. Total virus production at different
times (0–16 h) post-infection was determined by TCID50 assay on
Hep2 cells. Each point represents the mean (± standard deviation) of
virus titres from ﬁve different experiments.
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Met149 ﬁ Trp in VP3 is located in the inner surface of the
capsid (data not shown), where the N-termini of capsid pro-
teins interact, contributing to the integrity of the virion [24].
Nucleotide and amino acid substitutions were also identi-
ﬁed in the 2A–3D non-structural genomic region of iso-
lates 742 and MB1 (data not shown). The reversion at
nucleotide 6203 (C ﬁ U (His73 ﬁ Tyr)) of the 3D poly-
merase coding region, which has been correlated with the
attenuated and thermosensitive phenotype of the Sabin 1
vaccine strain [4], was not identiﬁed in the 3D region of iso-
late MB1. Other mutations in 2A–3D coding regions
appeared rarely and with no obvious preferences, and will
not be considered further.
Neutralizing capacity with human antisera
The levels of immunity towards all three OPV isolates and
Sabin vaccine strains of the western Greek population of the
1–10-year, 11–20-year, 21–30-year and 31–40-year age
groups were measured. Pooled (Table 4) or individual (data
not shown) sera were tested against each poliovirus strain.
Table 4 shows the statistical analysis of the log10 reciprocal
NT titres against OPV isolates and Sabin vaccine strains.
Members of the 1–40-year age group (both pooled and
individual sera) showed no signiﬁcant differences in NT titres
against OPV isolates in comparison with the Sabin vaccine
strains.
A signiﬁcant decrease in NT titre was observed from the
1–10-year age group to the 21–30-year age group for both
poliovirus types (P1 and P3). An increase in NT titre was
observed from the 21–30-year age group to the 31–40-year
age group for poliovirus types 1 and 3. However, this
increase was signiﬁcant only for poliovirus type 1 (Table 4).
In the neutralization assay with individual sera, no signiﬁ-
cant differences in NT titres were observed for poliovirus
type 1 between the 1–10-year, 11–20-year, 21–30-year and
31–40-year age groups. For poliovirus type 3, the results are
consistent with those of pooled sera. Sequential decreases in
NT titre were observed from the 1–10-year age group to
the 11–20-year and 21–30-year age groups, with the ﬁrst
being signiﬁcant.
The mean values of NT titres of the four age groups
against each poliovirus strain with pooled sera showed no
signiﬁcant differences in comparison with those of individual
sera (data not shown).
Discussion
The OPV strains are genetically unstable. Thermosensitivity
of reproduction (the Rct-40 marker), antigenic modiﬁcations
and one-step growth curve experiment have been used as
indirect markers of reversion to neurovirulence [4,26,27].
Reversions of the known attenuating mutations in OPV
strains and intertypic recombination have been identiﬁed as
the underlying causes of the phenotypic changes and increased
neurovirulence of poliovirus isolates [6–8]. Natural recombi-
nants of Sabin vaccine origin have been isolated from VAPP
patients [9,18]. Administration of trivalent OPV provides opti-
mal conditions for multiple infections of human intestinal
target cells, thus favouring the possibility of intermolecular
recombination between heterotypic viral genomes [28].
In this study, we determined phenotypic traits such as
thermosensitivity, growth kinetics and neutralizing capacity
with human antisera of three OPV isolates, and attempted to
correlate them with genomic modiﬁcations.
Two Sabin 1 isolates, one non-recombinant (522) and one
bi-recombinant (742), were tested. The presence of muta-
tions at known determinants of attenuation and thermosen-
sitivity and of the rare recombination event (S1/S3/S2) did
not affect the growth phenotype of isolate 742 at either
37C or 40C, as it replicated similarly to the Sabin 1
vaccine strain. However, it showed partial reversion to a
TABLE 4. Statistical analysis of the log10 reciprocal neutralization test (NT) titres (pooled sera) against Sabin vaccine strains
and oral poliovirus vaccine (OPV) isolates
Serotype
Virus
strain
Mean values of log10 reciprocal NT
titres of four age groups, 1–10,
11–20, 21–30 and 31–40 years
(each consisting of the pooled sera
from ten individuals) against each
poliovirus straina
Mean values of log10 reciprocal NT titres against all polioviruses of the
same serotype in each age group: 1–10, 11–20, 21–30 or 31–40 years (each
consisting of the pooled sera from ten individuals)b
1–10 11–20 21–30 31–40
1 Sabin 1 2.50 2.50 (p 1.0) 2.50 (p 1.0) 2.20 (p 1.0) 2.70 (p 1.0)
522 2.50
742 2.42 (p 0.391)
3 Sabin 3 2.42 2.80 (p 0.275) 2.05 (p 0.068) 1.90 (p 0.068) 2.50 (p 0.068)
MB1 2.20 (p 0.215)
aMean values of all three OPV isolates have no signiﬁcant differences from the respective values of Sabin vaccine strains according to Student’s t-test.
bMean values in italic for each poliovirus serotype have no signiﬁcant differences according to ANOVA.
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thermoresistant phenotype (Rct value = 2.00). The discrep-
ancy in the results between the two assays may correlate
with the fact that they show viral multiplication for different
time periods. Isolate 522 showed a thermosensitive pheno-
type in both the Rct test (Rct value = 3.5) and the one-step
growth curve test (ﬂat curve at 40C). However, it showed
a higher viral yield than the Sabin 1 vaccine strain at both
37C and 40C throughout the infectious life cycle (0–16 h
post-infection). In general, the presence of many determi-
nants of thermosensitivity scattered along the whole genome
of the Sabin 1 vaccine strain makes the reversion of Sabin 1
isolates to a thermoresistant phenotype difﬁcult [4]. It is
noteworthy that isolate 522 showed a higher virus titre
(2.5 log10 unit) than the Sabin 1 vaccine strain at the initial
stages of the infectious life cycle (0, 1 and 2 h post-infec-
tion). This initial difference leads to a higher virus titre of
isolate 522 than of the Sabin 1 vaccine strain throughout the
infectious life cycle, and may originate from the different
adsorption and/or penetration properties of isolate 522
from those of the Sabin 1 vaccine strain. The presence of
mutations in antigenic sites of isolate 522 (Ala59 ﬁ Glu and
Asp80 ﬁ Asn in VP3, and Ile90 ﬁ Met in VP1) may be
responsible for the difference in properties between iso-
late 522 and the Sabin 1 vaccine strain. Because of the
structural proximity and even overlapping of antigenic sites
and the capsid regions that interact with poliovirus recep-
tors, it seems reasonable to hypothesize that the amino
acids likely to be replaced in antigenic sites may interfere
with optimal virus–cell recognition. Moreover, the mutation
Ile257 ﬁ Val, which is situated in the hydrocarbon-binding
pocket of VP1 that interacts with a sphingosine molecule,
may contribute to the different adsorption and/or penetra-
tion properties of isolate 522.
The recombinant Sabin 3 isolate MB1 showed a thermo-
sensitive phenotype in both the Rct test (Rct value = 4.5)
and the one-step growth curve test (blocking of its growth
at 40C). Moreover, isolate MB1 showed a similar viral
yield to that of the Sabin 3 vaccine strain at the ﬁnal stages
of the infectious life cycle (8 and 16 h post-infection). Con-
sequently, the presence of mutations at known determi-
nants of attenuation and thermosensitivity (U472C in the
5¢-NCR, Thr6 ﬁ Ile in VP1) does not affect its phenotype.
However, the amino acid substitutions Asp129 ﬁ Glu,
Met130 ﬁ Arg, Val136 ﬁ Leu and Ile258–Val in VP1 may
be responsible for the earlier increase in titre of iso-
late MB1 (2 h post-infection) than of the Sabin 3 vaccine
strain (4 h post-infection), resulting in a difference in titre
of 1.5 log10 units at 4 h post-infection. These residues,
which are situated in the canyon and in the hydrocarbon-
binding pocket of VP1, may lead to different adsorption
and/or penetration properties of isolate MB1 from those of
the Sabin 3 vaccine strain.
The capacity of human antisera to neutralize OPV isolates
was also evaluated. More speciﬁcally, the levels of immunity
towards all three OPV isolates and Sabin vaccine strains of
the western Greek population of the 1–10-year, 11–20-year,
21–30-year and 31–40-year age groups was investigated. No
signiﬁcant differences from the homotypic Sabin strains were
observed in the capacity of OPV isolates to be neutralized in
both assays with pooled or individual sera. The presence of
mutations in antigenic sites of isolates 522 and 742 did not
affect their antigenic properties. The above reinforces the
notion that the driving force behind antigenic alterations of
OPV is not immune evasion, but negative selection of unfa-
vourable mutations interfering with optimal virus–cell recog-
nition [11].
The results of our study showed a signiﬁcant decrease in
immunity level from the 1–10-year age group to the 21–30-
year age group (pooled sera) for both poliovirus types 1 and
3. These ﬁndings are consistent with those reported in previ-
ous studies [21,29]. An increase in NT titre was observed
from the 21–30-year age group to the 31–40-year age group
for both poliovirus types 1 and 3, which is consistent with
the results of our previous study [21].
For both poliovirus types, the highest NT titres were
observed in the 1–10-year age group, indicating a good
response to vaccination. The lowest NT titre was observed in
the 21–30-year age group towards poliovirus type 3, indicat-
ing an unsatisfactory level of immunity against poliovirus
type 3 in young adults. These results are consistent with
those of previous studies [21,29,30]. The presence of the low-
est NT titre in the 21–30-year age group towards poliovirus
type 3 suggests the need for a booster dose of monovalent
Sabin 3 vaccine to ensure personal and herd immunity.
In the post-eradication era of wild polioviruses, the only
remaining sources of poliovirus infection worldwide will be
vaccine-derived polioviruses. As the majority of countries
certiﬁed as being polio-free have switched from OPV to IPV,
and taking into consideration the fact that IPV does not
induce the same immunity levels as OPV, importation of
recombinant evolved derivatives of vaccine strains would
have serious implications for public health. Our study under-
lines the need for poliovirus surveillance. The repeated
occurrence of highly divergent pathogenic poliovirus strains
that have retained Sabin-like antigenic properties presents a
serious challenge to the current poliovirus surveillance strat-
egy. Phenotypic markers such as one-step growth curve anal-
ysis and the Rct assay, along with genomic analysis, are
effective markers for the estimation of neurovirulence of
OPV isolates. Additionally, there is a vital need for immuno-
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logical studies in all age groups, in order to allow reconsider-
ation of the current vaccination policies and to avoid epi-
demics caused by the circulation of highly evolved OPV
derivatives.
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